[The value of determining antibodies to DNA in patients with purulent diseases of the lungs].
Anti-DNA antibody titers are elevated in the patients with purulent diseases of the lungs and antibodies to nDNA appear that are undetectable in normal subjects. These data correlate with the inflammatory process activity in the lungs, with the diameter of the decayed cavity, disease duration, and efficacy of therapy. Dynamic titration of antibodies to DNA (particularly nDNA) over the course of the disease appears to be an important prognostic test reflecting the stability of autoimmune impairments and the efficacy of the therapeutic scheme used in the treatment of patients with purulent diseases of the lungs.